Advantages of CG0070 Over Standard Care for Non-Muscle Invasive Bladder Cancer

Video

The chief executive officer of CG Oncology discussed the role of CG0070 in patients who are unresponsive and responsive to Bacillus Calmette-Guerin immunotherapy.

“Our oncolytic virus would essentially allow us to only target cancer cells and not normal cells, sparing the healthy tissue. So, there will be a toxicity and safety profile advantage. Also, we think we'll be able to better supply and serve the community with our manufacturing process versus BCG, which is really based on 100-year-old manufacturing process.”

Bacillus Calmette-Guerin (BCG) bacteria is a common intravesical immunotherapy for treating early-stage bladder cancer. While the established treatment has long demonstrated efficacy, CG Oncology believes that its novel immunotherapy, CG0070, has advantages over the bacteria including ease of manufacturing and specific targeting to cancer cells.

CG0070 is an oncolytic immunotherapy that uses a genetically modified oncolytic adenovirus delivered through a catheter to target and destroy bladder tumor cells through their defective retinoblastoma pathway.

CG Oncology recently dosed the first patient in the phase 2 CORE-001 trial (NCT04387461) of CG0070 in combination with pembrolizumab (Keytruda; Merck) for non-muscle invasive bladder cancer unresponsive to BCG in December 2020. The trial aims to evaluate the safety and efficacy of CG0070 plus Keytruda in up to 35 patients.

GeneTherapyLive spoke with Arthur Kuan, chief executive officer, CG Oncology, to learn more about the potential advantages of CG0070 compared with BCG.

REFERENCE
CG Oncology announces first patient dosed in phase 2 clinical trial of CG0070, an oncolytic immunotherapy, in combination with KEYTRUDA (pembrolizumab) for non-muscle-invasive bladder cancer unresponsive to bacillus calmette-guerrin. News release. CG Oncology. December 9, 2020. https://www.biospace.com/article/releases/cg-oncology-announces-first-patient-dosed-in-phase-2-clinical-trial-of-cg0070-an-oncolytic-immunotherapy-in-combination-with-keytruda-pembrolizumab-for-non-muscle-invasive-bladder-cancer-unresponsive-to-bacillus-calmette-guerin/
Related Videos
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.